Screen-detected asymmetry at 62 with BI-RADS 4B core biopsy — assessment, discordance, DCIS counsel and recall craft

Station brief

She is 62, asymptomatic, and frightened by the recall letter. The DBT service that found her detects more invasive cancer than mammography alone (TOSYMA 7.1 vs 4.8 per 1000) — which also means it recalls and biopsies more tissue, including benign disease.^[15]

Expected management

• Normalise the recall first. Recall does not mean cancer: biennial programmes recall roughly one-third of women at least once per decade, with first screens near 10.6% — she is experiencing the programme's known cost, not a diagnosis.^[40]
• Read the 4B report aloud as a plan. BI-RADS 4B carries about a 22% biopsy predictive value (between 7.6% for 4A and 69.3% for 4C) — tissue diagnosis is mandatory, and the number sets expectations without pretending certainty.^[27]
• Choose image-guided core needle biopsy. Core sensitivity (87%) beats fine-needle (74%) with similar specificity, and large-core series show 97% sensitivity with 94% surgical agreement — the assessment standard for a 16 mm asymmetry.^[30][31]
• Pre-consent the DCIS branch. If core shows DCIS, about one in four proves invasive at excision — higher with high grade, size over 20 mm, mass pattern or palpability — so her non-palpable 16 mm lesion sits mid-risk and earns excision correlation, not surveillance assumptions.^[32]
• Counsel DCIS as local control, not rescue. Surgery, radiotherapy and optional endocrine therapy cut local events with no survival effect; low-risk surveillance exists only inside trial-grade follow-up with explicit uncertainty — grade and size decide which conversation she joins.^[36]
• Manage both discordance directions. Benign core against 4B imaging (especially with mass or distortion features) means re-biopsy or excision; malignant core means clip, multidisciplinary review, and staging — concordance, documented, every time.^[27]
• Close with recall craft. Give a clear reason for recall, who attends with her, appointment length, who she sees and which tests follow, plus nurse-specialist access after the all-clear — the communication bundle recalled women actually ask for.^[41]

Examiner probes

• What changes if she were 32 with a palpable lump? (Triple assessment in full — under-40 cancers are rare but a lump multiplies odds more than eleven-fold, so youth never rules out biopsy when suspicion exists.)^[34]
• What changes with extremely dense breasts? (DENSE supplemental-MRI discussion with interval and false-positive halves quoted — 2.5 versus 5.0 per 1000 against 79.8 per 1000.)^[21]
• What changes if core shows a high-risk lesion (atypia, papillary) rather than DCIS? (Same concordance discipline the one-in-four DCIS upgrade rule demands — re-biopsy or excise, never reassure against the imaging.)^[32]